The legal action centers on accusations that Immutep violated the Securities Exchange Act by concealing unfavorable data from its TACTI-004 study. While the company reported strong progress in a January 30, 2026, SEC filing, the complaint alleges management was already aware that the trial would fail to meet its primary efficacy endpoints. When these details surfaced, the resulting market reaction led to significant shareholder losses.
Immutep Faces Shareholder Lawsuit Over Alleged TACTI-004 Disclosure Failures
Investors who purchased Immutep Limited securities between March 24, 2025, and March 12, 2026, face a critical deadline to join a class action lawsuit. The Schall Law Firm is spearheading the litigation, alleging that the biotech company misled shareholders regarding the efficacy of its TACTI-004 clinical trial for eftilagimod alfa.
Brian Schall, lead counsel at the Los Angeles-based firm, is urging affected investors to come forward before the July 6, 2026, deadline. Because the class remains uncertified, shareholders currently remain absent members of the potential litigation. Those seeking to discuss their legal standing or potential recovery options may contact the firm directly at 310-301-3335.
Comments (0)
No comments yet. Be the first!